A Follow-up Study to Evaluate the Long-term Post Treatment Effects of Peginterferon Alfa-2a (PEG-IFN) in Patients With HBeAg Positive Chronic Hepatitis B From the Original Study WV19432 (NEPTUNE).

Trial Profile

A Follow-up Study to Evaluate the Long-term Post Treatment Effects of Peginterferon Alfa-2a (PEG-IFN) in Patients With HBeAg Positive Chronic Hepatitis B From the Original Study WV19432 (NEPTUNE).

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Apr 2016

At a glance

  • Drugs Peginterferon alfa-2a (Primary)
  • Indications Hepatitis B
  • Focus Biomarker; Pharmacodynamics; Therapeutic Use
  • Acronyms SON of NEPTUNE
  • Sponsors Roche
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 17 Apr 2016 Results (n=383) assessing HBeAg seroconversion (SC) rates 5 years after completion of treatment were presented at The International Liver Congress™ 2016.
    • 10 Feb 2016 Treatment arm (from 1 to 4), design keyword (randomised & parallel), inclusion and exclusion criteria have been changed, as reported by ClinicalTrial.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top